



Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Correction to: *Nature Medicine*
<https://doi.org/10.1038/s41591-023-02704-x>,
published online 4 December 2023.

<https://doi.org/10.1038/s41591-024-02835-9>

Published online: 31 January 2024



Karim Fizazi , Arun A. Azad , Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones , Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye , Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren & Neeraj Agarwal

In the version of the article initially published, the top right label in Fig. 4e, now reading “Median PSF2”, was a duplicate of the top right label in Fig. 4d. The error has been corrected in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024